Mydecine Innovations Group (Mydecine Innovations Group) Debt-to-Equity : -0.84 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Mydecine Innovations Group Debt-to-Equity?

Mydecine Innovations Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.07 Mil. Mydecine Innovations Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $4.00 Mil. Mydecine Innovations Group's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-4.82 Mil. Mydecine Innovations Group's debt to equity for the quarter that ended in Sep. 2023 was -0.84.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Mydecine Innovations Group's Debt-to-Equity or its related term are showing as below:

MYCOF' s Debt-to-Equity Range Over the Past 10 Years
Min: -15.97 Med: 0.03 Max: 61.47
Current: -0.84

During the past 10 years, the highest Debt-to-Equity Ratio of Mydecine Innovations Group was 61.47. The lowest was -15.97. And the median was 0.03.

MYCOF's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.285 vs MYCOF: -0.84

Mydecine Innovations Group Debt-to-Equity Historical Data

The historical data trend for Mydecine Innovations Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Debt-to-Equity Chart

Mydecine Innovations Group Annual Data

Trend

Dec13

Aug14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

24.92

0.03

0.90

21.32

-1.33

Mydecine Innovations Group Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															-1.26	-1.33	-0.62	-0.58	-0.84

Competitive Comparison of Mydecine Innovations Group's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Mydecine Innovations Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mydecine Innovations Group's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mydecine Innovations Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Mydecine Innovations Group's Debt-to-Equity falls into.

Mydecine Innovations Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Mydecine Innovations Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.063	+	3.457)	/	-2.65
	=	-1.33

Mydecine Innovations Group's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.065	+	4.002)	/	-4.817
	=	-0.84

Mydecine Innovations Group (OTCPK:MYCOF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Mydecine Innovations Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mydecine Innovations Group (Mydecine Innovations Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (OTCPK:MYCOF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MYIG:UK 0NF0:Germany MYCO:Canada

Address

789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2

Website

https://www.mydecine.com

Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.